Cancer cocktail trial halted: what we know
NCT ID NCT02959437
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 32 times
Summary
This early-stage trial tested a combination of three drugs—azacitidine, pembrolizumab, and epacadostat—in 70 people with advanced solid tumors, including non-small cell lung cancer and colorectal cancer. The goal was to see if the combination was safe and could shrink tumors. However, the study was terminated, meaning it stopped early, so we have limited information on its effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Churchill Hospital
Oxford, Ox37le, United Kingdom
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Sarah Cannon
Nashville, Tennessee, 37203, United States
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
Univ De Navarra
Pamplona, 31008, Spain
-
University College London Hospitals (Uclh)
London, W1t7ha, United Kingdom
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Pennsylvania Health System
Philadelphia, Pennsylvania, 19014, United States
-
University of Washington
Seattle, Washington, 98109, United States
-
Vall D Hebron Univ
Barcelona, 08035, Spain
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
azacitidine, pembrolizumab, and epacadostat
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
The trial was terminated early, so results are limited. The combination may cause significant side effects, and it is unclear if it will work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.